Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

NCT07491211 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Osimertinib
Stereotactic Radiation

Interventions

DRUG: Osimertinib
RADIATION: intracranial stereotactic radiotherapy

Sponsor

Fudan University